Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 82009-032

The graph depicts the proportion of patients who had a relapse during the study with two treatments: placebo and duloxetine delayed-release capsules. The X-axis shows the number of days between randomization and relapse, while the Y-axis shows the proportion of patients. The graph indicates that patients taking duloxetine capsules had a lower proportion of relapse than those taking the placebo.*

This text appears to be a graph showing the percentage of patients improved with either a placebo or a certain medication (DULEamg) taken once daily. The percentage improvement in pain from baseline is also indicated. However, the specific details and conclusions that can be drawn from the graph are unclear without more context.*

This data appears to be a chart showing the percentage of patients who experienced improvement while taking a placebo or a specific medication at different dosage levels. It also includes a graph depicting the percent improvement in pain from baseline for the medication. However, without more context or a clear indication of what medication is being tested, it is difficult to provide additional information or draw any conclusions from the data.*

Each capsule of this medication contains 2.4 mg of duloxetine hydrochloride USP and comes in a container of 500 capsules. The medication is manufactured by Towa Pharmaceutical Europe, S.L. in Spain and is distributed by Qualient Pharmaceuticals Health LLG in Grand Cayman, Cayman Islands. The recommended storage temperature is 25°C (77°F) with excursions permitted from 15-30°C (50-46°F). The medication is a delayed-release capsule that requires a prescription. Dosage information can be found in the accompanying literature. It is important to keep this medication out of the reach of children and dispense in a tightly closed container. The pharmacist should also provide a medication guide to each patient. If you have any questions about this medication, consult your healthcare provider.*

Each capsule contains 33.7 mg of duloxetine hydrochloride USP equivalent to 30 mg duloxetine. The medication should be stored at 25°C (77°F), with excursions permitted to 15-30°C (59-86°F), and kept out of the reach of children. It is dispensed in a tightly closed container. The accompanying literature must be checked for dosage information. The medication guide should be provided separately to each patient. Manufactured by Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, and manufactured for Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. Rx Only.*

Each capsule of this medication contains 67.3 mg of duloxetine hydrochloride USP which is equivalent to 60 mg duloxetine. The medication should be stored at a temperature of 25°C (77°F) with a range of permissible excursions from 15-30°C (59-86°F), as stated in the USP Controlled Room Temperature guidelines. The literature accompanying this product has information on dosages. The medication needs to be kept out of reach of children and must be dispensed in a tightly closed container. The medication is available in a set of 1000 capsules which come under the NDC 82009-032-10 code. Pharmacists must provide the Medication Guide separately to each patient. The medication is manufactured by Towa Pharmaceutical Europe, S.L. in Martoreles, (Barcelona), Spain, and is manufactured for Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands.*

Each capsule of this medication contains duloxetine hydrochloride USP, manufactured by Towa Pharmaceutical Europe in Spain. The delayed-release capsules come in a bottle of 30 with a dosage that should be found in the accompanying literature. It should be kept at a temperature of 25°C (77°F) with excursions permits of 15-30°C (50-46°F). The medication should be dispensed in a tightly closed container by a pharmacist and the medication guide should be provided separately to each patient. It is Rx only and should be kept out of the reach of children.*